Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience

doi:10.4239/wjd.v15.i3.463

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2238)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1264

Figures (1-5)

106

Tables (1-4)

116

Sum=1569

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

131

Download

199

Sum=330

Publishing Process of This Article

Item

Count

Browse

Download

133

Sum=208

Mar 15, 2024 (publication date) through Aug 24, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Diabetes. Mar 15, 2024; 15(3): 463-474
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.463

Table 3 Follow-up metabolic/clinical/lab parameters for canagliflozin

Clinical/lab/parameter	Baseline, median (IQR; n)	6 months F/U, median (IQR; n)	12 months, median (IQR; n)	Latest, median (IQR; n)	P value (baseline vs latest)
HbA1c	80 (25.5; 160)	67.5 (20; 132)^b	67 (16.3; 128)^b	66 (28; 135)	< 0.001
Weight	100 (28.3; 125)	97.6 (27.5; 91)^a	98.3 (30.4; 74)	95.3 (27.5; 58)	< 0.001
BMI	35.1 (8.1; 73)	-	-	32.5 (9.38; 50)	< 0.001
Systolic BP	145 (18; 121)	-	145 (21.3; 84)	138 (22.8; 64)	0.041
Diastolic BP	84 (18; 121)	-	80.5 (11.2; 84)^a	79.5 (19; 64)	0.013
Albuminuria (> 3 mmol/mg)	14.1 (42.6; 40)	17.1 (30.4; 12)	7.3 (12.3; 21)^a	8.9 (23.7; 28)	0.043

^aP < 0.05.

^bP < 0.01.

BMI: Body mass index; BP: Blood pressure; HbA1c: Glycated hemoglobin; IQR: Interquartile range.

Citation: Islam L, Jose D, Alkhalifah M, Blaibel D, Chandrabalan V, Pappachan JM. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience. World J Diabetes 2024; 15(3): 463-474
URL: https://www.wjgnet.com/1948-9358/full/v15/i3/463.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i3.463